Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT06132048Recruiting
Testing a smartphone app for cystic fibrosis
This study tests a smartphone app called MuCopilot that helps you track your cystic fibrosis symptoms at home. Researchers want to see if the app is easy to use and can give accurate information about your condition.
RouenAges 18 years+ - NCT07449000Recruiting
Losartan for corneal scar treatment
This trial tests if losartan, a common blood pressure medicine, can help reduce corneal scars. It may be an option for adults with a stable corneal scar that has been present for at least one month.
Monterrey, Nueo LeonAges 18 years+ - NCT07447102RecruitingPhase 2
Study of BC006 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07442682Enrolling by invitation
Studying cystic fibrosis in adults at a Belgian center
This trial gathers information about adults with cystic fibrosis at the Erasme Hospital in Belgium. Your participation helps doctors better understand the condition and how it affects quality of life.
BrusselsAges 18 years+ - NCT06251687Recruiting
Cryobiopsy for diagnosing progressive pulmonary fibrosis
This trial is testing a new, less invasive way to take a lung tissue sample (called transbronchial cryobiopsy) to help diagnose progressive pulmonary fibrosis (PPF). It may help doctors find the cause of your lung scarring without needing a larger surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT05802264RecruitingPhase 1
Inhaled amphotericin B for healthy volunteers and cystic fibrosis
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
Canberra, Australian Capital TerritoryAges 16 years+ - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT06313827Recruiting
Online program to prevent flare-ups in cystic fibrosis
This trial tests an online program designed to help people with cystic fibrosis avoid exacerbations (sudden worsening of symptoms). You participate from home using a device with internet, camera, and microphone.
ValenciaAges 6 years+ - NCT05818319Recruiting
Tracking kidney urine effects after a short pause in CF therapy
This study checks how a common cystic fibrosis (CF) medicine affects urine markers after briefly stopping it and then restarting. The goal is to better understand whether the treatment shift changes kidney-related signals in people with CF.
Aarhus C, Central JutlandAges 18 years+ - NCT06836453Recruiting
New sweat test for cystic fibrosis diagnosis
This trial tests a new device that measures how your sweat glands react to a common asthma medication. It aims to better classify people with cystic fibrosis or related diseases, and also includes healthy volunteers and carriers.
BrusselsAges Any age - NCT07373288Recruiting
HOXB7 and lung markers in pulmonary fibrosis
This study looks at a protein called HOXB7 and other markers in lung tissue and blood to better understand pulmonary fibrosis. It may help researchers find new ways to diagnose or treat the disease.
ModenaAges 18–80 - NCT07369414Recruiting
NTM Germs in CF Homes: A Household Study
This study looks at whether people with cystic fibrosis (CF) can pick up nontuberculous mycobacteria (NTM) from their home environment. It compares homes of people with CF who have NTM to those who don't, to see where germs might be hiding.
Borstel, Schleswig-HolsteinAges Any age - NCT07363304Recruiting
How ETI therapy affects body and gut in cystic fibrosis
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
Bari, BariAges 2 years+ - NCT07359742Recruiting
Detecting liver scarring in chronic liver disease
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
BrusselsAges 18 years+ - NCT07345052Recruiting
Study on systemic sclerosis in western Sweden
This study is looking at people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect internal organs) to learn more about the disease. You may join if you have been diagnosed with this condition and meet a few other requirements.
Gothenburg, SwedenAges 18 years+ - NCT07342920Recruiting
Smoking and vaping in adults with cystic fibrosis
This study looks at how many adults with cystic fibrosis smoke or vape (use e-cigarettes). It aims to understand how common these habits are in this group.
StrasbourgAges 18 years+ - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT07312305Recruiting
Small airways test in idiopathic pulmonary fibrosis
This study measures how well the small airways in your lungs work if you have idiopathic pulmonary fibrosis (IPF). It aims to find better ways to assess the disease and could lead to improved care.
Milan, LombardyAges 18 years+ - NCT07314229Recruiting
Breathing limits during exercise in cystic fibrosis patients on ETI
This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.
LilleAges 18 years+ - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT07303140Recruiting
Liver stiffness in young people with glycogen storage disease type III
This study looks at liver stiffness (a sign of scarring, called fibrosis) in children and young adults with type III glycogen storage disease. Researchers want to see how common liver fibrosis is in this group and how it changes over time, using a non-invasive ultrasound-like test called elastography.
StrasbourgAges 1 month–21 years
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 417 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.